

TAAR1 transgenic animal

The present invention provides genetic constructs comprising DNA encoding TAAR1 and methods for producing non-human transgenic animals comprising within their genome transgenic DNA encoding TAAR1. Furthermore, the present invention provides non-human transgenic animals comprising within their genomes transgenic DNA
5 encoding TAAR1. Moreover, transgenic animals overexpressing TAAR1, as well as the methods of producing them are also provided. The invention also relates to the use of these animals as a tool for assessing TAAR1 function, for further characterization of known TAAR1 ligands and for identifying as yet unknown ligands of TAAR1, for analyzing TAAR1 signal transduction mechanisms, for analyzing the physiological
10 function of TAAR1 *in vivo*, and for characterizing agonists, antagonists or modulators of TAAR1. Furthermore, the invention relates to the use of the said TAAR1 transgenic animals for studying the function of TAAR1 and their use as a model for identifying and testing the therapeutic effect of compounds regarding neurological, psychiatric and metabolic disorders.

15 Trace amines (TAs) are endogenous compounds related to biogenic amine neurotransmitters which are present in the mammalian nervous system in trace amounts. The intense research efforts on the pharmacology and metabolism of trace amines during the last decades has been triggered by their tight link to a variety of highly prevalent conditions such as depression, schizophrenia, anxiety disorders, bipolar disorder,
20 attention deficit hyperactivity disorder, neurological diseases such as Parkinson Disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, obesity and dyslipidemia (Reviewed in: Lindemann & Höner, 2005; Branchek, T.A. and Blackburn, T.P. (2003) *Curr. Opin. Pharmacol.* 3, 90-97; Premont, R.T., Gainetdinov, R.R., Caron, M.G. (2001) *Proc. Natl. Acad. Sci.* 98, 9474-9475.;
25 Davenport, A.P. (2003) *Curr. Opin. Pharmacol.* 3, 127-134.). However, a detailed understanding of the physiology of trace amines at the molecular level has only become possible with the recent identification of a novel family of G protein-coupled receptors termed Trace Amine Associated Receptors (TAARs; Lindemann, L., Ebeling, M., Kratochwil, N.A., Bunzow J.R., Grandy, D.K., Hoener, M.C. (2005) *Genomics* 85, 372-
30 385; Bunzow, et al. (2001) *Mol. Pharmacol.* 60, 1181-1188; Borowsky, B., et al., (2001). *Proc. Natl. Acad. Sci. U. S. A.* 98, 8966-8971). Some of these receptors display sensitivity to trace amines, and their unique pharmacology and expression pattern make

these receptors prime candidates for targets in drug development in the context of several diseases, some of which previously had been linked to trace amines. Progress in understanding the physiological relevance of TAARs and their ligands on the systems level critically depends on a detailed knowledge of their expression pattern, their pharmacology and the modes of signal transduction. In this context, compounds acting as agonists, antagonists or positive or negative modulators on TAARs, as well as transgenic animal models overexpressing the TAAR1 receptor are essential tools for dissecting the molecular function of this receptor family and to fully understand their potential relevance as targets in drug development.

The present invention therefore provides genetic constructs comprising a DNA sequence encoding TAAR1 operatively linked to a promoter.

According to a first aspect, there is provided a transgenic mouse, whose genome comprises a genetic construct comprising a DNA sequence encoding murine or human TAAR1 operatively linked to a mouse Thy1 promoter.

According to a second aspect, there are provided descendants of the transgenic mouse as defined above.

According to a third aspect, there is provided a cell line or primary cell culture derived from a transgenic mouse or its descendants as defined above.

According to a fourth aspect, there is provided a tissue or organotypic brain slice cultures derived from a transgenic mouse or its descendants as defined above.

According to a fifth aspect, there is provided a tissue explant or an organ explant or a culture thereof, derived from a transgenic mouse or its descendants as defined above.

According to a sixth aspect, there is provided a tissue extract or a cell extract, derived from a transgenic mouse or its descendants as defined above.

According to a seventh aspect, there is provided use of a non-human transgenic animal as defined above, or a cell line or primary cell culture as defined above, or a tissue or organotypic brain slice cultures as defined above or a tissue or an organ explant or culture thereof as defined above, or a tissue or cell extract as defined above as a model for identifying and testing the therapeutic effect of a compound in disorders comprising depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's Disease, neurodegenerative disorders such as Alzheimer's Disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders,

diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

According to an eighth aspect, there is provided use of a transgenic mouse as defined above, or a cell line or primary cell culture as defined above, or a tissue or organotypic brain slice cultures as defined above, or a tissue or an organ explant or culture thereof as defined above, or a tissue or cell extract as defined above as a tool for assessing TAAR1 function.

According to a ninth aspect, there is provided use of a transgenic mouse as defined above, or a cell line or primary cell culture as defined above, or a tissue or organotypic brain slice cultures as defined above, or a tissue or an organ explant or culture thereof as defined above, or a tissue or cell extract as defined above as a tool for identifying unknown ligands of TAAR1.

According to a tenth aspect, there is provided use of a transgenic mouse as defined above, or a cell line or primary cell culture, or a tissue or organotypic brain slice cultures as defined above or a tissue or an organ explant or culture thereof as defined above, or a tissue or cell extract as defined above as a tool for determining the specificity of compounds acting on TAAR1.

According to an eleventh aspect, there is provided use of a transgenic mouse as defined above, or a cell line or primary cell culture as defined above, or a tissue or organotypic brain slice cultures as defined above, or a tissue or an organ explant or culture thereof as defined above, or a tissue or cell extract as defined above for studying the intracellular trafficking of TAARs or of other cellular components linked to TAARs.

The sequence of TAAR1 gene can be derived from any animal. Preferably the sequence of taar1 derives from a mammal, more preferably, the sequence of taar1 is a human (NM_138327, SEQ ID NO:1) or a mouse sequence (NM_053205, SEQ. ID NO:2).

The promoter may be a neuronal promoter. In a preferred embodiment the promoter is a tissue-specific promoter. A tissue-specific promoter may be any promoter, which controls and directs expression of a gene in a tissue-specific manner, e.g., in brain tissue (brain-specific), in muscle tissue, in liver tissue, in kidney tissue, etc. Preferably, the promoter provides specific expression in the central nervous system (CNS). Most preferably, the promoter is the mouse Thy1 promoter (Ingraham, H.A., Lawless, G.M., Evans, G.A. (1986)

The mouse Thy-1.2 glycoprotein gene: complete sequence and identification of an unusual promoter. *J Immunol.* 136, 1482-1489).

The promoter may also be a controllable promoter. A controllable promoter may be any promoter, which controls the expression of a transgene in a regulatable and/or inducible fashion, e.g., by addition of specific inducer or repressor substances. Several inducible bacterial promoter are known in the art (Schultze N, Burki Y, Lang Y, Certa U, Bluethmann H; *Nat Biotechnol* 1996; 14(4): 499-503; van der Neut R; Targeted gene disruption: applications in neurobiology; *J Neurosci Methods* 1997; 71(1): 19-27; Liu HS, Lee CH, Lee CF, Su JJ, Chang TY; Lac/Tet dual-inducible system functions in mammalian cell lines. *Biotechniques.* 1998; 24(4): 624-8, 630-2).

The term "promoter" as used herein refers to DNA regions which control the expression of a coding sequence.

The term "transgenic DNA" as used herein describes DNA artificially introduced and incorporated into an organism.

The term "sequence of *taar1* gene" as used herein, describes the DNA sequence encoding TAAR1.

5

The genetic construct may additionally comprises a Kozak Sequence. Preferably, the genetic construct comprises an optimized Kozak sequence such as for example the sequence: tccacc. The Kozak Sequence is a DNA sequence that surrounds the ATG start signal for the translation of an mRNA (Kozak, M., An analysis of 5'-noncoding
10 sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 15 (1989) 8125-8148.).

In a preferred embodiment, the genetic construct comprise additionally an N-terminal influenza hemagglutinin viral leader sequence. In another preferred embodiment the genetic construct comprises additionally an epitope marker such as for example M1-
15 FLAG epitope. In another preferred embodiment, the genetic construct comprise additionally a Met-Gly linker. In a even more preferred embodiment the genetic construct comprises an N-terminal influenza hemagglutinin viral leader sequence, an M1-FLAG epitope and a Met-Gly linker (Bunzow, et al. (2001) Mol. Pharmacol. 60, 1181-1188; X.M. Guan, T.S. Kobilka, B.K. Kobilka (1992) Enhancement of membrane insertion and
20 function in a type IIIb membrane protein following introduction of a cleavable signal peptide. J. Biol. Chem. 267, 21995-21998).

Preferably, the genetic construct is as depicted in Figure 1 or Figure 2.

More preferably, the genetic construct is Thy1-hsTAAR1 incorporated in the plasmid pThy1-hsTAAR1 deposited under accession number DSM 17761 (deposited under the
25 Budapest Treaty at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH (DSMZ) with an effective deposition date of 30.11.2005), or the genetic construct is Thy1-mmTAAR1 incorporated in the plasmid pThy1-mmTaar1 deposited under accession number DSM 17760 (deposited under the Budapest Treaty at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH (DSMZ) with an effective
30 deposition date of 30.11.2005).

The present invention further provides a method of producing a transgenic non-human animal whose genome comprise transgenic DNA encoding TAAR1, comprising

- a) introducing a genetic construct as described above into a non-human zygote or an non-human embryonic stem cell,
- 5 b) generating a transgenic non-human animal from said zygote or embryonic stem cell, and thereby,
- c) producing a transgenic non-human animal whose genome comprises transgenic DNA encoding TAAR1.

A further embodiment of the invention provides a method of producing a non-human
10 transgenic animal expressing transgenic TAAR1 comprising

- a) introducing a genetic construct as described above into a non-human zygote or an non-human embryonic stem cell,
- b) generating a transgenic non-human animal from said zygote or embryonic stem cell, and thereby,
- 15 c) producing a transgenic non-human animal expressing transgenic TAAR1.

The zygote or embryonic stem cell may derive from any non-human animal. Preferably, the zygote or embryonic stem cell derives from a rodent. More preferably, the zygote or embryonic stem cell derives from a mouse.

20 Preferably, the zygote used in the methods described above is a C57BL/6J zygote. Zygotes used in the art which may also be used in the methods of this invention comprise, but are not limited to, CBA/ zygotes, BALB/c zygotes, DBA/2 zygotes and SV129 zygotes.

Embryonic stem cells used in the art which may also be used in the methods of this
25 invention comprise but are not limited to embryonic stem cells derived from mouse strains such as C57BL/6, CBA/, BALB/c, DBA/2 and SV129. Preferably, embryonic stem cells derived from C57BL/6 mice are used (Seong, E et al (2004) *Trends Genet.* 20, 59-62; Wolfer, D.P. et al., *Trends Neurosci.* 25 (2002): 336-340).

The present invention further provides the transgenic non-human animal produced by any of the above described methods.

The term "transgenic TAAR1" as used herein describes TAAR1 protein originating from DNA artificially introduced and incorporated into an organism.

5 The term "transgenic animal" as used herein describes an animal comprising transgenic DNA in their genome. This transgenic DNA may be incorporated somewhere in the genome.

For example, the transgenic animals may be generated by injecting above described DNA construct into the pronucleus of zygotes, transferring these injected zygotes into
10 pseudo-pregnant foster mothers, breeding founder animals resulting from the oocytes to wild type animals, testing the offspring resulting from these breedings for the presence of the synthetic DNA transgene construct, breeding hemizygous animals, optionally to generate homozygous transgenic animals.

Alternatively, the transgenic animals may be generated by introducing the genetic
15 construct as described above into embryonic stem cells and subsequently selecting embryonic stem cell clones for the presence of the transgene in the genome, verifying the presence of the transgene in the transformed embryonic stem cell clones, injecting the verified recombinant embryonic stem cells into blastocysts of wild type animals, transferring these injected blastocysts into pseudo-pregnant foster mothers, breeding
20 chimeras resulting from the blastocysts to wild type animals, testing the offspring resulting from these breedings for the presence of the transgene, breeding hemizygous animals, optionally to generate homozygous transgenic animals.

In one embodiment of the invention, transgenic non-human animals whose genome
25 comprises transgenic DNA encoding TAAR1 are provided. In a preferred embodiment the transgenic non-human animal comprises a genetic construct as depicted in Fig. 1 or a genetic construct as depicted in Fig. 2.

In another preferred embodiment, the transgenic non-human animal comprises a genetic construct Thy1-hsTAAR1 incorporated in the plasmid pThy1-hsTAAR1
30 deposited under accession number DSM 17761 (deposited under the Budapest Treaty at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH (DSMZ) with an effective deposition date of 30.11.2005), or the genetic construct is Thy1-mmTaaR1 incorporated in the plasmid pThy1-mmTaaR1 deposited under accession number DSM 17760 (deposited under the Budapest Treaty at the Deutsche Sammlung von

Microorganismen und Zellkulturen GmbH (DSMZ) with an effective deposition date of 30.11.2005).

In another embodiment transgenic non-human animals expressing transgenic TAAR1 are provided. In a preferred embodiment, the transgenic TAAR1 is expressed in a tissue-specific manner, i.e., in the brain. In another embodiment, the expression of the transgenic TAAR1 may be temporally controlled, e.g., by addition of specific inducer or repressor substances. In a preferred embodiment, the transgenic non-human animal overexpresses the transgenic TAAR1 protein. In a more preferred embodiment, the transgenic TAAR1 is overexpressed in tissue-specific manner.

The transgenic non-human animal may be any non-human animal known in the art, which may be used for the methods of the invention. Preferably, the transgenic non-human animal is a mammal, more preferably the transgenic non-human animal is a rodent. Most preferably, the transgenic animal of the invention is a mouse.

The transgenic non-human animals described above may be analyzed genetically, molecularly and behaviorally.

The present invention also relates to descendants of the transgenic non-human animals as provided by the invention, obtained by breeding with the same or with another genotype. A descendant is used herein as a synonym for progeny.

The transgenic animals may be used for preparing primary cell cultures, and for the preparation of secondary cell lines derived from primary cell preparations of these animals or their descendants. Furthermore, the transgenic animals can be used for the preparation of tissue or organotypic brain slice cultures. Moreover, the transgenic animals can be used for the preparation of tissue explants or organ explants or cultures thereof. In addition, the transgenic animal may be used for the preparation of tissue or cell extracts such as membrane or synaptosomal preparations.

The present invention further provides a cell line or primary cell culture derived from the transgenic non-human animals as provided by the invention or their descendants.

Furthermore, the present invention provides a tissue or organotypic brain slice culture, derived from the transgenic non-human animals as provided by the invention or their descendants.

In addition, the present invention provides tissue explants or organ explants or cultures thereof, derived from the transgenic non-human animals as provided by the invention or their descendants.

Moreover, the present invention provides a tissue extract or a cell extract, derived from
5 the transgenic non-human animals as provided by the invention or their descendants.

Cell culture based models can be prepared by two methods. Cell cultures can be isolated from the non-human transgenic animals or prepared from established cell cultures using the same genetic constructs as described above with standard cell
10 transfection techniques.

Integration of the genetic construct comprising transgenic DNA encoding TAAR1, can be detected by various methods comprising genomic Southern blot and PCR analysis using DNA isolated from tissue biopsies of the animals.

It will be apparent to the person skilled in the art that there are a large number of
15 analytical procedures which may be used to detect the expression of the transgenic DNA comprising methods at the RNA level comprising mRNA quantification by reverse transcriptase polymerase chain reaction (RT-PCR) or by Northern blot, *in situ* hybridization, as well as methods at the protein level comprising histochemistry, immunoblot analysis and binding studies. Quantification of the expression levels of the
20 transgene can moreover be determined by the ELISA technology, which is common to those knowledgeable in the art.

Quantitative measurement can be accomplished using many standard assays. For example, transcript levels can be measured using RT-PCR and hybridization methods including RNase protection, Northern blot analysis, and RNA dot blot analysis. Protein
25 levels can be assayed by ELISA, Western blot analysis, and by comparison of immunohistochemically or histochemically stained tissue sections. Immunohistochemical staining, enzymatic histochemical stainings as well as immuno-electron microscopy can also be used to assess the tissue distribution of the endogenous as well as of the overexpressed TAAR1 protein.

30 The transgenic animals of the invention may be further characterized by methods known in the art, comprising immunohistochemistry, electron microscopy, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) and by behavioral and physiological studies addressing neurological, sensory, and cognitive functions as well as physiological (e.g. metabolic) parameters. Examples of behavioral tests and

physiological examinations are: Spontaneous behavior, behavior related to cognitive functions, pharmacologically-disrupted behavior, grip strength test, horizontal wire test, forced swim test, rotarod test, locomotor activity test, prepulse inhibition test, Morris water maze test, Y-maze test, light-dark preference test, passive and active avoidance tests, marble burying test, plus maze test, learned helplessness test, stress-induced hyperthermia, measuring food consumption and development of body weight over time, measuring body temperature and energy consumption under resting and basal conditions and during heat and cold exposure, determining the thermoneutral zone, determining the food assimilation coefficient (e.g. by bomb calorimetry), determining the energy assimilation and the energy content of feces, determining the respiratory coefficient e.g. for analysis of the carbohydrate and lipid metabolism, determining the substrate utilization and energy expenditure during food restriction, determining the oxygen consumption, CO₂- and heat production e.g. by indirect calorimetry, measuring the heart rate and blood pressure under resting, basal and stress conditions (e.g. by telemetry), determining the body composition (e.g. regarding water content, fat amount and fat-free mass).

A further objective of the present invention is the use of a non-human transgenic animal, a cell line or primary cell culture, a tissue or organotypic brain slice cultures, a tissue explant or an organ explant or culture thereof, a tissue or cell extract derived from the transgenic non-human animals as provided by the invention or its descendants as a model for identifying and testing the therapeutic effect of a compound in disorders comprising depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders such as posttraumatic stress disorder, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's Disease, neurodegenerative disorders such as Alzheimer's Disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

Moreover, the present invention provides the use of a non-human transgenic animal, a cell line or primary cell culture, a tissue or organotypic brain slice cultures, a tissue explant or an organ explant or culture thereof, a tissue or cell extract derived from the transgenic non-human animals as provided by the invention or its descendants as a model for studying the susceptibility to compounds inducing disorders comprising depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders such as posttraumatic stress disorder, psychotic disorders such as

schizophrenia, neurological diseases such as Parkinson's Disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of
5 sleep and circadian rhythm, and cardiovascular disorders.

A further objective of the present invention is the use of a non-human transgenic animal, a cell line or primary cell culture, a tissue or organotypic brain slice cultures, a tissue explant or an organ explant or culture thereof, a tissue or cell extract derived from the
10 transgenic non-human animals as provided by the invention or its descendants as a tool for assessing TAAR1 function.

Furthermore, the present invention provides the use of a non-human transgenic animal, a cell line or primary cell culture, a tissue or organotypic brain slice cultures, a tissue explant or an organ explant or culture thereof, a tissue or cell extract derived from the
15 transgenic non-human animals as provided by the invention or its descendants as a tool for identifying unknown ligands of TAAR1 and their characterization.

Moreover, the present invention provides the use of a non-human transgenic animal, a cell line or primary cell culture, a tissue or organotypic brain slice cultures, a tissue explant or an organ explant or culture thereof, a tissue or cell extract derived from the
20 transgenic non-human animals as provided by the invention or its descendants as a tool for determining the specificity of compounds acting on TAAR1.

A further objective of the present invention is the use of a non-human transgenic animal, a cell line or primary cell culture, a tissue or organotypic brain slice cultures, a tissue explant or an organ explant or culture thereof, a tissue or cell extract derived from the
25 transgenic non-human animals as provided by the invention or its descendants for studying the intracellular trafficking of TAARs or of other cellular components linked to TAARs.

The invention further provides genetic constructs, methods, transgenic animals, test systems and uses substantially as described herein before especially with reference to the
30 foregoing examples.

Having now generally described this invention, the same will become better understood by reference to the specific examples, which are included herein for purpose of illustration only and are not intended to be limiting unless otherwise specified, in connection with the following figures.

Figures:

Figure 1 shows a schematic representation of the genetic construct huTAAR-TG incorporated in the plasmid pThy1-hsTAAR1 (not shown). The control region of the Thy1 gene was used to control the expression of a human TAAR1 cDNA in the brain.

- 5 A: The 6.8 kb control region of the Thy1 gene in which a 1.5 kbp BanI-XhoI fragment located on exons 2 and 4 was replaced by a XhoI cloning site thereby deleting Exon 3. The present exons (Exon 1, Exon 2, Exon 4) of the Thy1 gene are indicated in black.
B: The XhoI site in the Thy1 gene was used to insert an XhoI fragment containing the human TAAR1 cDNA (hsTAAR1, white). The human TAAR1 cDNA was fused with a
10 N-terminal tag (FLAG, hatched).

C: The N-terminal tag is shown as nucleotide sequence and as its translation into single letter amino acid code. The Kozak sequence (small letters) is followed by a signal sequence of the influenza hemagglutinin virus (capital letters), the FLAG epitope tag (capital letters, underlined) and the Met-Gly linker (capital letters, italic).

- 15 Figure 2: shows a schematic representation of the mmTAAR-TG construct incorporated in the plasmid pThy1-mmTaarl (not shown). The control region of the Thy1 gene was used to control the expression of a human Taar1 cDNA in the brain.
A: The 6.8 kb control region of the Thy1 gene in which a 1.5 kbp BanI-XhoI fragment located on exons 2 and 4 was replaced by a XhoI cloning site thereby deleting Exon 3.
20 The present exons (Exon 1, Exon 2, Exon 4) of the Thy1 gene are indicated in black.
B: The XhoI site in the Thy1 gene was used to insert an XhoI fragment containing the human Taar1 cDNA (hsTaarl, white). The human Taar1 cDNA was fused with a N-terminal tag (FLAG, hatched).

- C: The N-terminal tag is shown as nucleotide sequence and as its translation into single
25 letter amino acid code. The Kozak sequence (small letters) is followed by a signal sequence of the influenza hemagglutinin virus (capital letters), the FLAG epitope tag (capital letters, underlined) and the Met-Gly linker (capital letters, italic).

- Figure 3: shows the genotyping of transgenic lines and B6-Tg(TAAR1)1 and B6-Tg(Taar1)2 by means of PCR. DNA was analyzed for the presence of the transgene,
30 indicating the respective genotypes of the animals. Marker XIV (Roche) was used as molecular weight standard.

A: B6-Tg(Taar1)2: Ethidium bromide stained agarose gel of PCR reaction to detect the presence of the Thy1-mmTaarl sequences in tail biopsies of mice.

- M: Marker XIV, 1: mouse biopsy 9; 2: mouse biopsy 10; 3: positive control; 4: negative
35 control.

B: B6-Tg(TAAR1)1: Ethidium bromide stained agarose gel of PCR reaction to detect the presence of the Thy1-hsTaarl sequences in tail biopsies of mice.

M: Marker XIV, **1:** mouse biopsy 34; **2:** mouse biopsy 35; **3:** positive control; **4:** negative control.

Examples

Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated.

- 5 Example 1: Construction of the pThy1-hsTAAR1 and pThy1-mmTaar1 plasmid constructs

PCR amplification of the cDNA sequences

Oligonucleotides were designed based on the published mouse TAAR1 coding sequence (Genbank Accession No. NM_053205, SEQ. ID NO: 2) or human TAAR1
10 coding sequence (Genbank Accession No. NM_138327, SEQ. ID NO: 1) or on other elements of the pThy1-hsTAAR1 and pThy1-mmTaar1 plasmids and they were obtained from Microsynth AG (Balgach, Switzerland). All molecular cloning techniques were carried out essentially according to Sambrook et. al. (Molecular Cloning: A laboratory manual. 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor.) and the
15 instructions of the suppliers of kits and enzymes.

The coding sequences of human (hsTAAR1) and mouse (mmTaar1) were amplified by PCR from genomic C57BL/6 DNA (mmTaar1) or a cloned coding sequence pcDNA3.1-humTar01 (hsTAAR1).

The 5'-oligonucleotides, hTar1-tg-3c (SEQ. ID NO: 21) and mTar1-tg-1c (SEQ. ID
20 NO: 27), were designed to contain a XhoI site, a Kozak sequence, sequences coding for a signal sequence of the influenza hemagglutinin virus, the FLAG epitope Tag and a Met-Gly linker (Fig. 1C, Fig. 2C). The 3'-oligonucleotides, hTar1-tg-4nc (SEQ. ID NO: 22) and mTar1-tg-2nc (SEQ. ID NO: 28) introduce a XhoI site immediately downstream of the stop codon.

25

• *hsTAAR1-PCR amplification*

*0.5 ng/μl template DNA (pcDNA3.1-humTar01), 300 μM dNTPs (PCR Nucleotide Mix, Roche Diagnostics, Mannheim, Germany), 1 μM of oligonucleotide huTar1-tg-3c, 1 μM of oligonucleotide huTar1-tg-4nc 1x PCR buffer 3 (part of the Expand High Fidelity
30 PCR System; Roche Diagnostics, Mannheim, Germany), 0,075 U/μl Expand Polymerase Mix (part of the Expand High Fidelity PCR System; Roche Diagnostics, Mannheim, Germany)) in a total volume of 20 μl were incubated with the following protocol: 94°C 2*

min., 10× (94°C 10 sec., 60°C 30 sec., 68°C 2 min.), 20× (94°C 10 sec., 60°C 30 sec., 68°C 2 min.+15 sec/cycle) 68°C 7 min, ∞ 12°C on a PCR Thermocycler MJ Research PTC-200 (MJ Research Inc., Watertown, USA).

5 • *mmTaar1-PCR amplification*

0.5 ng/μl template DNA (genomic C57BL/6 DNA), 300 μM dNTPs (PCR Nucleotide Mix, Roche Diagnostics, Mannheim, Germany), 1 μM of oligonucleotide mTar1-tg-1c, 1 μM of oligonucleotide mTar1-tg-2nc, 1x PCR buffer 3 (part of the Expand High Fidelity PCR System; Roche Diagnostics, Mannheim, Germany), 0,075 U/μl Expand Polymerase Mix (part of the Expand High Fidelity PCR System; Roche Diagnostics, Mannheim, Germany)) in a total volume of 20 μl were incubated with the following protocol: 94°C 2 min., 10× (94°C 10 sec., 60°C 30 sec., 68°C 2 min.), 20× (94°C 10 sec., 60°C 30 sec., 68°C 2 min.+15 sec/cycle) 68°C 7 min, ∞ 12°C on a PCR Thermocycler MJ Research PTC-200 (MJ Research Inc., Watertown, USA).

15

Cloning into the cloning vector pCMV

The resulting 1.1kb PCR amplification products were separated using agarose gel-electrophoresis followed by purification with the StrataPrep PCR Purification Kit (Stratagene, La Jolla, CA, USA). The purified PCR products were then subcloned into the SrfI site of the pCMVScript vector of the pCMV PCR Cloning Kit (Invitrogen-Gibco, Carlsbad, CA, USA) according to the kits instructions. The resulting vector are pCMV-mmTaar1 and pCMV-hsTAAR1.

Orientation and sequence were confirmed by sequencing using the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) and an ABIPrism 310 Genetic Analyzer with the oligonucleotides depicted in table 1:

Vector	Oligonucleotides used for sequencing		Resulting sequence:
	Term	SEQ. ID NO:	
pCMV-hsTAAR1	T3 forward	29	SEQ. ID NO: 5
pCMV-hsTAAR1	T7 reverse	30	SEQ. ID NO: 6
pCMV-hsTAAR1	hu-Tar 303c	17	SEQ. ID NO: 7

pCMV-hsTAAR1	hu-Tar 408nc	18	SEQ. ID NO: 8
pCMV-hsTAAR1	hu-Tar 695 c	19	SEQ. ID NO: 9
pCMV-hsTAAR1	hu-Tar 757 nc	20	SEQ. ID NO: 10
pCMV-mmTaar1	T3 forward	29	SEQ. ID NO: 11
pCMV-mmTaar1	T7 reverse	30	SEQ. ID NO: 12
pCMV-mmTaar1	mTar-293c	23	SEQ. ID NO: 13
pCMV-mmTaar1	mTar-345nc	24	SEQ. ID NO: 14
pCMV-mmTaar1	mTar-663c	25	SEQ. ID NO: 15
pCMV-mmTaar1	mTar-755nc	26	SEQ. ID NO: 16

Table 1: Sequencing reactions of pCMV-mmTaar1 and pCMV-hsTAAR1

The sequences of SEQ. ID. NOs: 5-10 were edited manually and the vector sequence of pCMV was omitted. They can be assembled to confirm the correct sequence of the pCMV-hsTAAR1 vector (SEQ. ID NO: 3).

- 5 The sequences of SEQ. ID. NOs: 11-16 were edited manually and the vector sequence of pCMV was omitted. They can be assembled to confirm the correct sequence of the pCMV-mmTaar1 vector (SEQ. ID NO: 4).

10 Cloning into the pThy vector

- The vector pCMV-mmTaar1 and pCMV-hsTAAR1 were used to generate the vectors pThy1-mmTaar1 and pThy1-hsTAAR1, respectively. To this end a pCMV-mmTaar1 and pCMV-hsTAAR1 were digested with XhoI and the resulting 1.1 kb fragment containing the Taar1 coding sequences were purified from agarose gels . They
15 were subsequently ligated into the vector pThy1 (Fig. 1A; Fig. 2A; Richards, J.G., Higgins, G.A., Ouagazzal, A.M., Ozmen, L., Kew, J.N., Bohrmann, B., Malherbe, P., Brockhaus, M., Loetscher, H., Czech, C., Huber, G., Bluethmann, H., Jacobsen, H. and Kemp, J.A. (2003) J. Neurosci. 23(26), 8989-9003)) that has been opened with the restriction enzyme XhoI.

- 20 The resulting vectors pThy1-mmTaar1 and pThy1-hsTAAR1 were confirmed using sequencing with Thy1-2c (SEQ. ID NO: 31) and restriction digests.

Deposition data: The plasmid comprising the genetic construct pThyl-mmTaar1 was deposited under the Budapest Treaty at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1 b, D-38124 Braunschweig, Germany, with an effective deposition date of 30.11.2005 under the
5 accession number DSM 17760.

The plasmid comprising the genetic construct pThyl-hsTAAR1 was deposited under the Budapest Treaty at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1 b, D-38124 Braunschweig, Germany, with an effective deposition date of 30.11.2005 under the accession number DSM 17761.

10

Example 2: Generating transgenic mouse lines B6-Tg(TAAR1)1 and B6-Tg(Taar1)2

All handling of animals was carried out in compliance with Swiss Federal and Cantonal laws on animal research, and permission for the generation and handling of the
15 mutant mouse line was specifically granted from the Kantonale Veterinärämte of Basel City with the Tierversuchgenehmigung No. 192.

The plasmids pThyl-mmTaar1 and pThyl-hsTAAR1 were digested with NotI and PvuI, followed by gel purification of the 7,6kb fragment containing the Thyl promotor and Taar1 sequences. These fragments of pThyl-mmTaar1 and pThyl-hsTAAR1 were
20 injected into the pronucleus of fertilized C57BL/6 oocytes which were subsequently transferred into the oviducts of pseudopregnant foster mothers essentially as described in (Gene Targeting. 1999, Second Edition, The Practical Approach Series, Oxford University Press, New York) and Hogan, B., Beddington, R., Costantini, F., und Lacy, E. (Manipulating the mouse embryo. 1994, Second Edition, Cold Spring Harbor Press, Cold
25 Spring Harbor). Offspring delivered by the foster mothers were considered as founder animals and analyzed for the presence of the respective transgenes in the genome.

To this end, genomic DNA was isolated from tail biopsies of adult animals with a MagNAPure LC system for nucleic acid purification (Roche Applied Science, Rotkreuz, Switzerland) according to the instructions of the manufacturer and analyzed for the
30 presence of the TAAR1 transgenes by means of PCR.

Transgenic animals comprising in their genome the genetic construct "Thyl-hsTAAR1" are designated as B6-Tg(TAAR1)1 and transgenic animals comprising in their genome the genetic construct "Thyl-mmTaar1" are designated as B6-Tg(Taar1)2.

- *Genotyping of B6-Tg(TAAR1)1*

0.5 ng/ μ l tail biopsy DNA, 200 μ M dNTPs (PCR Nucleotide Mix, Roche Diagnostics, Mannheim, Germany), 1 μ M of oligonucleotide Thy1-2c (SEQ. ID. NO: 31),
5 1 μ M of oligonucleotide huTar1-757-n (SEQ. ID NO:20)c, 1x PCR reaction buffer (Roche Diagnostics, Mannheim, Germany), 0,05 U/ μ l Taq DNA Polymerase (Roche Diagnostics, Mannheim, Germany)) in a total volume of 20 μ l were incubated with the following protocol: 94°C 2 min., 30x (94°C 20 sec., 60°C 30 sec., 72°C 50 sec) 72°C 7 min, ∞ 12°C on a PCR Thermocycler MJ Research PTC-200 (MJ Research Inc.,
10 Watertown, USA).

- *Genotyping of B6-Tg(Taar1)2*

0.5 ng/ μ l tail biopsy DNA, 200 μ M dNTPs (PCR Nucleotide Mix, Roche Diagnostics, Mannheim, Germany), 1 μ M of oligonucleotide mTar1-293-c, 1 μ M of
15 oligonucleotide Thy1-5-nc (SEQ. ID NO: 32), 1x PCR reaction buffer (Roche Diagnostics, Mannheim, Germany), 0,05 U/ μ l Taq DNA Polymerase (Roche Diagnostics, Mannheim, Germany)) in a total volume of 20 μ l were incubated with the following protocol: 94°C 2 min., 30x (94°C 20 sec., 64°C 30 sec., 72°C 50 sec) 72°C 7 min, ∞ 12°C on a PCR Thermocycler MJ Research PTC-200 (MJ Research Inc., Watertown,
20 USA).

The PCR products were analyzed by standard agarose gel electrophoresis as described in Sambrook et al. (1989). See figure 3 for an example of genotyping.

Three founders were identified with an insertion of the human TAAR1 construct
25 and designated as B6-Tg(TAAR1)1.6, B6-Tg(TAAR1)1.7 and B6-Tg(TAAR1)1.29.

Three founders were identified with an insertion of the murine Taar1 construct and designated as B6-Tg(Taar1)2.15, B6-Tg(Taar1)2.19 and B6-Tg(Taar1)2.27.

**Semiquantitative analysis of human TAAR1 and mouse TAAR1 expression,
30 respectively, in brain regions of the transgenic mouse lines B6-Tg(TAAR1)1 and B6-Tg(Taar1)2**

Offspring of the identified founders B6-Tg (TAAR1)1.6, B6-Tg(TAAR1)1.7 and B6-Tg(TAAR1)1.29 were tested for expression of mRNA coded by the constructs Thy1-hsTAAR1. Offspring of the identified founders B6-Tg(Taar1)2.15, B6-Tg(Taar1)2.19 and B6-Tg(Taar1)2.27 were tested for expression of mRNA coded by the constructs
5 Thy1-mm(Taar1).

To test for expression of the constructs Thy1-mm(Taar1) and Thy1-hsTAAR1 a real time PCR assay was used. To this end total RNA of mouse brains was isolated, transcribed into cDNA and detected with Real-Time PCR using a combination of primers and probe specific for the synthetic N-terminal Tag common to both constructs (Fig 1C,
10 Fig 2C).

RNA was prepared from tissue samples essentially according to Chomczynski and Sacchi (Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, Anal. Biochem. 162 (1987) 156-159.). In brief, mice 6 to 8 weeks of age were sacrificed, and total brains were removed and homogenized in 10× volumes
15 of Trizol Reagent (Invitrogen, Paisley, UK) in Lysing Matrix D tubes using a Fast Prep FP120 tissue homogenizer (Savant Instruments, Inc., Holbrook, N.Y.) at a setting of 6 for 20 s. The homogenates were extracted with 1/5 volume of Chloroform and subsequently precipitated using 2 volumes of isopropanol. The precipitated total RNA was washed with 80% Ethanol and dissolved in DEPC-H₂O. 100µg Total RNA was further purified
20 using the RNeasy Mini Protocol for RNA Cleanup of the RNeasy Mini Kit (Qiagen, Hilden, Germany) including a on-column DNase Digestion with the RNase-Free DNase Set (Qiagen, Hilden, Germany).

For cDNA synthesis the Omniscript Reverse Transkription Kit (Qiagen, Hilden, Germany) was used according to the instructions of the manufacturer. Briefly, 2µg total
25 RNA were mixed with 1µM oligo (dT)15 (Roche Diagnostics, Mannheim, Germany), 0.5mM of each dNTP (PCR Nucleotide Mix, Roche Diagnostics, Mannheim, Germany), 1x Buffer RT (Qiagen, Hilden, Germany), 10 U RNase Inhibitor (Roche Diagnostics, Mannheim, Germany) 1 µl Omniscript Reverse Transcriptase (Qiagen, Hilden, Germany) in a total volume of 20 µl. The reaction mix was incubated at 37°C for 1h.

30 Real time PCR was carried out using Custom designed Quantitect Gene expression assays according to the Quantitect Gene Expression Assay Handbook (Qiagen, Hilden, Germany). The transgene specific Quantitect Custom assay was designed to detect the synthetic N-terminal tag and consisted of a forward primer (SEQ. ID NO: 33), reverse
Primer (SEQ. ID NO: 34) and FAM labeled probe (SEQ. ID NO: 35). As control the
35 Yakima Yellow labeled QuantiTect Endogenous Control Assay (Mm Arbp 1 YY QuantiTect Gene Expression Assay, Qiagen, Hilden, Germany) against the housekeeping

gene murine Arbp (Acidic ribosomal phosphoprotein PO) was used. 10 µl QuantiTect Probe PCR Master Mix, 2µl Quantitect Assay Mix and 2µl cDNA were set up in white reaction plates (MJ Research Inc., Watertown, USA) on a DNA Engine Opticon 2 (MJ Research Inc., Watertown, USA) and real time PCR with the following temperature protocol were performed: 95°C 15 min., 45x (94°C 15 sec., 56°C 30 sec., 76°C 30 sec). C(T) values were calculated using the Opticon monitor Software (MJ Research Inc., Watertown, USA).

The results of one experiment are summarized in Table 2. In this experiment two mice each of the lines B6-Tg (TAAR1)1.6, B6-Tg(TAAR1)1.7, B6-Tg(TAAR1)1.29, B6-Tg(Taar1)2.15, B6-Tg(Taar1)2.19 and B6-Tg(Taar1)2.27 as well as two wildtype mice were sacrificed, cDNA was produced as described above and two PCR reactions were run for each mouse with the transgene specific Quantitect assay (Qiagen, Hilden, Germany) and, as control, one PCR reaction was run for each mouse with the Arbp specific Quantitect assay (see Table 2).

From wildtype mice, control reactions where the reverse transcriptase was not added, as well as water controls, C(T) values are obtained close or below to the threshold of detection (Table 2). On the other hand, the lines B6-Tg(TAAR1)1.7, B6-Tg(TAAR1)1.29, B6-Tg(Taar1)2.19 and B6-Tg(Taar1)2.27 express the transgenic construct, as C(T) values are within the range of plasmid positive controls (Table 2).

20

Sample:	Transgene specific probe: C(T) +/- standard deviation	Housekeeping gene (Arbp) probe: C(T) +/- standard deviation
B6-Tg (TAAR1)1.6	36.4 +/- 4.2	30.7 +/- 0.6
B6-Tg(TAAR1)1.7	24.6 +/- 0.8	28.5 +/- 2.4
B6-Tg(TAAR1)1.29	27.2 +/- 1.6	31.6 +/- 2.2
B6-Tg(Taar1)2.15	36.2 +/- 3.4	29.6 +/- 0.1
B6-Tg(Taar1)2.19	23.7 +/- 0.4	30.0 +/- 1.8
B6-Tg(Taar1)2.27	24.9 +/- 0.6	28.0 +/- 1.3
wildtype	39.6 +/- 3.5	28.1 +/- 1.1
Blank (H ₂ O)	below threshold	nd
B6-Tg(Taar1)2.19 without reverse transcription	below threshold	nd
B6-Tg(TAAR1)1.7 without reverse transcription	below threshold	nd
pThyl-mmTaarl (10 ³ copies)	33.6	nd
pThyl-mmTaarl (10 ⁴ copies)	29.1	nd

pThy1-mmTaar1 (10^5 copies)	25.4	nd
pThy1-mmTaar1 (10^6 copies)	22.2	nd
pThy1-mmTaar1 (10^7 copies)	19.1	nd

Table 2: Results of the real time PCR analysis of cDNAs derived from B6-Tg(TAAR1)1 and B6-Tg(Taar1)2 mouse brains for the presence of the mRNA transcripts. (C(T): number of PCR cycles; nd: not determined).

Claims

1. A transgenic mouse, whose genome comprises a genetic construct comprising a DNA sequence encoding murine or human TAAR1 operatively linked to a mouse Thy1 promoter.
2. A transgenic mouse according to claim 1 wherein the transgenic mouse is C57BL/6.
3. A transgenic mouse according to any one of the claims 1 to 2 overexpressing TAAR1 protein.
4. Descendants of the transgenic mouse according to any of the claims 1 to 3
5. A cell line or primary cell culture derived from a transgenic mouse or its descendants according to any one of claims 1 to 4.
6. A tissue or organotypic brain slice cultures derived from a transgenic mouse or its descendants according to any one of the claims 1 to 4.
7. A tissue explant or a organ explant or a culture thereof, derived from a transgenic mouse or its descendants according to any one of the claims 1 to 4.
8. A tissue extract or a cell extract, derived from a transgenic mouse or its descendants according to any one of the claims 1 to 4.
9. Use of a non-human transgenic animal according to claims 1 to 4, or a cell line or primary cell culture according to claim 5, or a tissue or organotypic brain slice cultures according to claim 6 or a tissue or an organ explant or culture thereof according to claim 7, or a tissue or cell extract according claim 8 as a model for identifying and testing the therapeutic effect of a compound in disorders comprising depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's Disease, neurodegenerative disorders such as Alzheimer's Disease, epilepsy, migraine, hypertension, substance abuse

and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

10. Use of a transgenic mouse according to claims 1 to 4, or a cell line or primary cell culture according to claim 5, or a tissue or organotypic brain slice cultures according to claim 6, or a tissue or an organ explant or culture thereof according to claim 7, or a tissue or cell extract according claim 8 as a tool for assessing TAAR1 function.
11. Use of a transgenic mouse according to claims 1 to 4, or a cell line or primary cell culture according to claim 5, or a tissue or organotypic brain slice cultures according to claim 6, or a tissue or an organ explant or culture thereof according to claim 7, or a tissue or cell extract according claim 8 as a tool for identifying unknown ligands of TAAR1.
12. Use of a transgenic mouse according to claims 1 to 4, or a cell line or primary cell culture according to claim 5, or a tissue or organotypic brain slice cultures according to claim 6 or a tissue or an organ explant or culture thereof according to claim 7, or a tissue or cell extract according claim 8 as a tool for determining the specificity of compounds acting on TAAR1.
13. Use of a transgenic mouse according to claims 1 to 4, or a cell line or primary cell culture according to claim 5, or a tissue or organotypic brain slice cultures according to claim 6, or a tissue or an organ explant or culture thereof according to claim 7, or a tissue or cell extract according claim 8 for studying the intracellular trafficking of TAARs or of other cellular components linked to TAARs.

22
TAAR1 transgenic animal
Abstract

The present invention relates to genetic constructs comprising DNA encoding TAAR1 and their use to generate animals transgenic for TAAR1, transgenic animals comprising in their genome transgenic DNA encoding TAAR1, their use and methods of generating
5 these animals.

(FIG. 1)

SEQUENCE LISTING

<110> F. Hoffmann-La Roche

<120> TAAR1 transgenic animal

<130> 23400 EP

<150> EP 05111699.4

<151> 2005-12-05

<160> 35

<170> PatentIn version 3.3

<210> 1

<211> 1020

<212> DNA

<213> Homo sapiens

<400> 1

```
atgatgccct tttgccacaa tataattaat atttcctgtg tgaaaaacaa ctggtcaaatt    60
gatgtccgtg cttccctgta cagtttaatg gtgctcataa ttctgaccac actcgttggc    120
aatctgatag ttattgtttc tatatcacac ttcaaacaac ttcatacccc aacaaattgg    180
ctcattcatt ccatggccac tgtggacttt cttctggggg gtctgggtcat gccttacagt    240
atgggtgagat ctgctgagca ctgttggtat tttggagaag tcttctgtaa aattcacaca    300
agcaccgaca ttatgctgag ctgagcctcc attttccatt tgtctttcat ctccattgac    360
cgctactatg ctgtgtgtga tccactgaga tataaagcca agatgaatat cttggttatt    420
tgtgtgatga tcttcattag ttggagtgtc cctgctgttt ttgcatttgg aatgatcttt    480
ctggagctaa acttcaaagg cgctgaagag atatattaca aacatgttca ctgcagagga    540
ggttgctctg tcttcttttag caaaatatct ggggtactga cttttatgac ttctttttat    600
atacctggat ctattatgtt atgtgtctat tacagaatat atcttatcgc taaagaacag    660
gcaagattaa ttagtgatgc caatcagaag ctccaaattg gattggaaat gaaaaatgga    720
atttcacaaa gcaaagaaag gaaagctgtg aagacattgg ggattgtgat gggagttttc    780
ctaatatgct ggtgcccttt ctttatctgt acagtcattg acccttttct tcaactacatt    840
attccaccta ctttgaatga tgtattgatt tggtttggtc acttgaactc tacatttaat    900
ccaatggttt atgcattttt ctatccttgg tttagaaaag cactgaagat gatgctgttt    960
ggtaaaattt tccaaaaaga ttcattccagg tgtaaattat ttttggaatt gagttcatag   1020
```

<210> 2

<211> 999

<212> DNA

<213> Mus musculus

<400> 2

```
atgcatcttt gccacgctat cacaaacatt tcccacagaa acagcgactg gtcaagagaa    60
gtccaagctt ccctgtacag cttaatgtca ctcataatcc tggccactct ggttggaac    120
ttaatagtaa taatttccat atcccatttc aagcaacttc atacaccac caactggctc    180
cttcactcca tggccattgt cgactttctg ctgggctgtc tgataatgcc ctgcagcatg    240
```

```

gtgagaactg ttgagcgctg ttggtatittt ggggaaatcc tctgtaaagt tcacaccagc 300
accgatatca tgctgagctc cgccctccatt ttccacttag ctttcatttc cattgaccgc 360
tactgtgctg tgtgtgaccc tttagagatac aaagccaaga tcaatatctc cactattctt 420
gtgatgatcc tcgttagttg gagccttcct gctgtttatg catttgggat gatcttcctg 480
gaactgaact taaaaggagt ggaagagctg tatcgagctc aggtcagcga cctgggcggc 540
tgttctccct tcttttagtaa agtatctggg gtactggcgt tcatgacttc cttctatata 600
cctggatctg ttatgttatt tgtttactat aggatatatt tcatagctaa aggacaagca 660
aggtcaatca atcgtagcaa tgttcaagtt ggattggaag ggaaaagcca agcaccacaa 720
agcaaggaaa caaaagccgc gaagacctta gggatcatgg tgggcgtttt cctcgtatgc 780
tggtgcccgt tctttctctg cacggctcctg gaccctttcc tgggctatgt tatcccaccc 840
tctctgaatg acgcactgta ttggtttggg tacttgaatt ctgccctcaa tccgatggtt 900
tatgcctttt tctatccctg gttcagaaga gccttgaaga tggttctcct tggtaaaatt 960
ttccaaaaag attcatctag gtctaagcta tttttgtaa 999

```

```

<210> 3
<211> 1116
<212> DNA
<213> Artificial

```

```

<220>
<223> Description of artificial sequence: XhoI fragment of genetic
construct Thy1-hsTAAR1 comprising hsTAAR1 cDNA fused with a
N-terminal FLAG tag.

```

```

<400> 3
ctcgagtcca ccatgaagac gatcatcgcc ctgagctaca tcttctgcct ggtgttcgcc 60
gactacaagg acgatgatga cgccatgggc atgatgccct ttgcccacaa tataattaat 120
atttcctgtg tgaaaaacaa ctggtcaaat gatgtccgtg cttccctgta cagtttaatg 180
gtgctcataa ttctgaccac actcgttggc aatctgatag ttattgtttc tatatcacac 240
ttcaaacaac ttcatacccc aacaaattgg ctcatcatt ccatggccac tgtggacttt 300
cttctggggg gtctgggtcat gccttacagt atggtgagat ctgctgagca ctgttggtat 360
tttgggagaag tcttctgtaa aattcacaca agcaccgaca ttatgctgag ctgagcctcc 420
attttccatt tgtctttcat ctccattgac cgctactatg ctgtgtgtga tccactgaga 480
tataaagcca agatgaatat cttggttatt tgtgtgatga tcttcattag ttggagtgtc 540
cctgctgttt ttgcatttgg aatgatcttt ctggagctaa acttcaaagg cgctgaagag 600
atatattaca aacatgttca ctgcagagga ggttgctctg tcttcttttag caaaatatct 660
ggggtactga cctttatgac ttctttttat atacctggat ctattatgtt atgtgtctat 720
tacagaatat atcttatcgc taaagaacag gcaagattaa ttagtgatgc caatcagaag 780
ctccaaattg gattggaaat gaaaaatgga atttcacaaa gcaaagaaag gaaagctgtg 840
aagacattgg ggattgtgat gggagttttc ctaatatgct ggtgcccttt ctttatctgt 900
acagtcatgg acccttttct tcactacatt attccaccta ctttgaatga tgtattgatt 960

```

tggttttgct acttgaactc tacatttaac ccaatggttt atgcattttt ctatccttgg 1020
tttagaaaag cactgaagat gatgctgttt ggtaaaattt tccaaaaaga ttcattccagg 1080
tgtaaattat ttttggaatt gagttcatag ctcgag 1116

<210> 4
<211> 1095
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: XhoI fragement of genetic construct Thy1-mmTaarl comprising mmTaarl cDNA fused with a N-terminal FLAG tag.

<400> 4
ctcgagtcca ccatgaagac gatcatcgcc ctgagctaca tcttctgcct ggtgttcgcc 60
gactacaagg acgatgatga cgccatgggc atgcattttt gccacgctat cacaacatt 120
tcccacagaa acagcgactg gtcaagagaa gtccaagctt cctgttacag cttaattgtca 180
ctcataatcc tggccactct ggttggcaac ttaatagtaa taatttccat atccccatttc 240
aagcaacttc atacacccac caactggctc cttcactcca tggccattgt cgactttctg 300
ctgggctgtc tgataatgcc ctgcagcatg gtgagaactg ttgagcgctg ttggtatttt 360
ggggaaatcc tctgtaaagt tcacaccagc accgatatca tgctgagctc cgccctccatt 420
ttccacttag ctttcatttc cattgaccgc tactgtgctg tgtgtgaccc tttgagatac 480
aaagccaaga tcaatatctc cactattctt gtgatgatcc tcgttagttg gagccttcct 540
gctgtttatg catttgggat gatcttctct gaactgaact taaaaggagt ggaagagctg 600
tatcgcagtc aggtcagcga cctgggcggc tgttctccct tctttagtaa agtatctggg 660
gtactggcgt tcatgacttc cttctatata cctggatctg ttatgttatt tgtttactat 720
aggatatatt tcatagctaa aggacaagca aggtcaatca atcgtagcaa tgttcaagtt 780
ggattggaag ggaaaagcca agcaccacaa agcaaggaaa caaaagccgc gaagacctta 840
gggatcatgg tgggcgtttt cctcgatgac tgggtgccct tctttctctg cagggtcctg 900
gaccctttcc tgggctatgt tatccacccc tctctgaatg acgcactgta ttggtttggg 960
tacttgaatt ctgccctcaa tccgatgggt tatgcctttt tctatccctg gtccagaaga 1020
gccttgaaga tggttctcct tggtaaaatt ttcaaaaaag attcatctag gtctaagcta 1080
tttttgaac tcgag 1095

<210> 5
<211> 410
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: Sequence resulting from sequencing the vector construct pCMV-hsTAAR1 with T3

<400> 5
ctcgagtcca ccatgaagac gatcatcgcc ctgagctaca tcttctgcct ggtgttcgcc 60
gactacaagg acgatgatga cgccatgggc atgatgccct ttggccacaa tataattaat 120

atctcctgtg tgaaaaacaa ctgggtcaa atggtccgtg cttccctgta cagtttaatg 180
gtgctcataa ttctgaccac actcgttggc aatctgatag ttattgtttc tatatcacac 240
ttcaaacac ttcatacccc aacaaattgg ctcatcatt ccatggccac tgtggacttt 300
cttctggggg gtctggtcat gccttacagt atggtgagat ctgctgagca ctgttggtat 360
tttgagaag tcttctgtaa aattcacaca agcaccgaca ttatgctgag 410

<210> 6
<211> 345
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: sequence resulting from sequencing of pCMV-hsTAAR1 with T7

<400> 6
aatcagaagc tccaaattgg attggaaatg aaaaatggaa tttcacaag caaagaaagg 60
aaagctgtga agacattggg gattgtgatg ggagttttcc taatatgctg gtgccctttc 120
tttatctgta cagtcattga cccttttctt cactacatta ttccacctac tttgaatgat 180
gtattgattt gggttggtta ctgaactct acatttaatc caatgggtta tgcatttttc 240
tatccttggg ttagaaaagc actgaagatg atgctgtttg gtaaaatttt ccaaaaagat 300
tcatccaggg gtaaattatt tttggaattg agttcatagc tcgag 345

<210> 7
<211> 490
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: sequence resulting from sequencing of pCMV-hsTAAR1 with hu-Tar 303c.

<400> 7
ctgttggtat tttggagaag tcttctgtaa aattcacaca agcaccgaca ttatgctgag 60
ctcagcctcc attttcatt tgtctttcat ctccattgac cgctactatg ctgtgtgtga 120
tccactgaga tataaagcca agatgaatat cttggttatt tgtgtgatga tcttcattag 180
ttggagtgtc cctgctgttt ttgcatttgg aatgatcttt ctggagctaa acttcaaagg 240
cgctgaagag atatattaca aacatgttca ctgcagagga gggtgctctg tcttctttag 300
caaaatatct ggggtactga cttttatgac ttctttttat atacctggat ctattatggt 360
atgtgtctat tacagaatat atcttatcgc taaagaacag gcaagattaa ttagtgatgc 420
caatcagaag ctccaaattg gattggaaat gaaaaatgga atttcacaaa gcaaagaaag 480
gaaagctgtg 490

<210> 8
<211> 358
<212> DNA
<213> Artificial

<220>

<223> Description of artificial sequence: sequence resulting from sequencing of pCMV-hsTAAR1 with hu-Tar 408nc.

<400> 8
ctcgagtcca ccatgaagac gatcatcgcc ctgagctaca tcttctgcct ggtgttcgcc 60
gactacaagg acgatgatga cgccatgggc atgatgccct ttgcccacaa tataattaat 120
atttcctgtg tgaaaaacaa ctggtcaaat gatgtccgtg cttccctgta cagtttaatg 180
gtgctcataa ttctgaccac actcgttggc aatctgatag ttattgtttc tatatcacac 240
ttcaaacac ttcatacccc aacaaattgg ctcatcatt ccatggccac tgtggacttt 300
cttctgggggt gtctggtcat gccttacagt atggtgagat ctgctgagca ctgttggt 358

<210> 9
<211> 370
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: sequence resulting from sequencing of pCMV-hsTAAR1 with hu-Tar 695c.

<400> 9
acaggcaaga ttaattagtg atgccaatca gaagctccaa attggattgg aaatgaaaaa 60
tggaatttca caaagcaaag aaaggaaagc tgtgaagaca ttggggattg tgatgggagt 120
tttcctaata tgctggtgcc ctttctttat ctgtacagtc atggaccctt ttcttcacta 180
cattattcca cctactttga atgatgtatt gatttggttt ggctacttga actctacatt 240
taatccaatg gtttatgcat ttttctatcc ttggtttaga aaagcactga agatgatgct 300
gtttggtaaa attttccaaa aagattcatc caggtgtaaa ttatttttgg aattgagttc 360
atagctcgag 370

<210> 10
<211> 386
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: sequence resulting from sequencing of pCMV-hsTAAR1 with hu-Tar 757nc.

<400> 10
acagtatggt gagatctgct gaggactggt ggtatttttg agaagtcttc tgtaaaattc 60
acacaagcac cgacattatg ctgagctcag cctccatttt ccatttgtct ttcactcca 120
ttgaccgcta ctatgctgtg tgtgatccac tgagatataa agccaagatg aatatcttgg 180
ttatttgtgt gatgatcttc attagttgga gtgtccctgc tgtttttgca tttggaatga 240
tctttctgga gctaaacttc aaaggcgctg aagagatata ttacaaacat gttcactgca 300
gaggaggttg ctctgtcttc tttagcaaaa tatctgggggt actgaccttt atgacttctt 360
tttatatacc tggatctatt atgtta 386

<210> 11
<211> 411
<212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: sequence resulting from sequencing of pCMV-mmTaarl with T3.

<400> 11

```
ctcgagtcca ccatgaagac gatcatcgcc ctgagctaca tcttctgcct ggtgttcgcc 60
gactacaagg acgatgatga cgccatgggc atgcactctt gccacgctat cacaacatt 120
tccccagaaa acagcgactg gtcaagagaa gtccaagctt ccctgtacag cttaatgtca 180
ctcataatcc tggccactct ggttggcaac ttaatagtaa taatttccat atcccatttc 240
aagcaacttc atacacccac caactggctc cttcactcca tggccattgt cgactttctg 300
ctgggctgtc tgataatgcc ctgcagcatg gtgagaactg ttgagcgctg ttggtatttt 360
ggggaaatcc tctgtaaagt tcacaccagc accgatatca tgctgagctc c 411
```

<210> 12

<211> 378

<212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: sequence resulting from sequencing of pCMV-mmTaarl with T7.

<400> 12

```
tataggatat atttcatagc taaaggacaa gcaaggtaa tcaatcgta gaattgtcaa 60
gttggaattg aagggaaaag ccaagcacca caaagcaagg aaacaaaagc cgcgaagacc 120
ttagggatca tggtagggcgt ttctctcgta tgctggtgcc cgttctttct ctgcacggtc 180
ctggaccctt tcttgggcta tggttatccca cctctctga atgacgcact gtattggttt 240
gggtacttga attctgcct caatccgatg gtttatgcct tttctatcc ctggttcaga 300
agagccttga agatggttct ccttggtaaa attttccaaa aagattcatc taggtctaag 360
ctatttttgt aactcgag 378
```

<210> 13

<211> 371

<212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: sequence resulting from sequencing of pCMV-mmTaarl with mTar-293c.

<400> 13

```
gtgagaactg ttgagcgctg ttggtatttt ggggaaatcc tctgtaaagt tcacaccagc 60
accgatatca tgctgagctc cgctccatt ttccacttag ctttcatttc cattgaccgc 120
tactgtgctg tgtgtgacct tttagatac aaagccaaga tcaatatctc cactattctt 180
gtgatgatcc tcgttagttg gaggcttctt gctgtttatg catttgggat gatcttcttg 240
gaactgaact taaaaggagt ggaagagctg tatcgagtc aggtcagcga cctgggcggc 300
tgttctcctt tctttagtaa agtatctggg gtactggcgt tcatgacttc cttctatata 360
cctggatctg t 371
```

<210> 14
<211> 292
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: sequence resulting from sequencing of pCMV-mmTaarl with mTar-345nc.

<400> 14
ctcgagtcca ccatgaagac gatcatcgcc ctgagctaca tcttctgcct ggtgttcgcc 60
gactacaagg acgatgatga cgccatgggc atgcatcttt gccacgctat cacaacatt 120
tcccacagaa acagcgactg gtcaagagaa gtccaagctt ccctgtacag cttaatgtca 180
ctcataatcc tggccactct ggttggcaac ttaatagtaa taatttccat atcccatttc 240
aagcaacttc atacaccac caactggctc cttactcca tggccattgt cg 292

<210> 15
<211> 391
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: sequence resulting from sequencing of pCMV-mmTaarl with T7.

<400> 15
gttatttggt tactatagga tatatttcat agctaaagga caagcaaggc caatcaatcg 60
tacgaatggt caagttggat tggaaggga aagccaagca ccacaaagca aggaacaaaa 120
agccgcgaag accttaggga tcatgggtggg cgttttcttc gtatgctggt gcccgttctt 180
tctctgcacg gtcttgacc ctttctggg ctatgttatt ccaccctctc tgaatgacgc 240
actgtattgg tttgggtact tgaattctgc cctcaatccg atggtttatg ctttttcta 300
tccctggttc agaagagcct tgaagatggt tctccttggt aaaattttcc aaaaagattc 360
atctagggtct aagctatttt tgtaactcga g 391

<210> 16
<211> 451
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: sequence resulting from sequencing of pCMV-mmTaarl with mTar-755nc.

<400> 16
cccaccaact ggctccttca ctccatggcc attgtcgact ttctgctggg ctgtctgata 60
atgccctgca gcatggtgag aactgttgag cgctgttggt attttgggga aatcctctgt 120
aaagttcaca ccagcaccga tatcatgctg agctccgcct ccattttcca cttagctttc 180
atttccattg accgctactg tgctgtgtgt gaccctttga gatacaaagc caagatcaat 240
atctccacta ttcttgatgat gatcctcggt agttggagcc ttctgctgt ttatgcattt 300
gggatgatct tcctggaact gaacttaaaa ggagtgggaag agctgtatcg cagtcaggtc 360

agcgacctgg gcggtgttc tcccttcttt agtaaagtat ctgggggtact ggcgttcacg 420
acttccttct atatacctgg atctgttatg t 451

<210> 17
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: oligonucleotide

<400> 17
cttctggggt gtctgggtcat g 21

<210> 18
<211> 22
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: oligonucleotide

<400> 18
gcataatgtc ggtgcttggtg tg 22

<210> 19
<211> 24
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: oligonucleotide

<400> 19
cctggatcta ttatgttatg tgtc 24

<210> 20
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: oligonucleotide

<400> 20
cttgccgtgtt ctttagcgat aag 23

<210> 21
<211> 112
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: oligonucleotide

<400> 21
gcctcgagtc caccatgaag acgatcatcg ccctgagcta catcttctgc ctggtgttcg 60
ccgactacaa ggacgatgat gacgccatgg gcatgatgcc cttttgccac aa 112

<210> 22
<211> 28
<212> DNA

<213> Artificial

<220>
<223> Description of artificial sequence: oligonucleotide

<400> 22
gcctcgagct atgaactcaa ttccaaaa 28

<210> 23
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: oligonucleotide

<400> 23
cgactttctg ctgggctgtc 20

<210> 24
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: oligonucleotide

<400> 24
caacagttct caccatgctg c 21

<210> 25
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: oligonucleotide

<400> 25
gtactggcgt tcatgacttc c 21

<210> 26
<211> 22
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: oligonucleotide

<400> 26
ccttgcttgt cctttagcta tg 22

<210> 27
<211> 115
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: oligonucleotide

<400> 27
gcctcgagtc caccatgaag acgatcatcg ccctgagcta catcttctgc ctggtgttcg 60
ccgactacaa ggacgatgat gacgccatgg gcatgcatct ttgccacgct atcac 115

<210> 28
<211> 28
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: oligonucleotide

<400> 28
gcctcgagtt acaaaaatag cttagacc 28

<210> 29
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: oligonucleotide

<400> 29
aattaaccct cactaaaggg 20

<210> 30
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: oligonucleotide

<400> 30
taatacgact cactataggg 20

<210> 31
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: oligonucleotide

<400> 31
gtgctccgtg gatctcaagc 20

<210> 32
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: oligonucleotide

<400> 32
ggatgatggc atgcagcact g 21

<210> 33
<211> 18
<212> DNA
<213> Artificial

<220>
<223> Description of artificial sequence: forward primer

<400> 33

gatcatcgcc ctgagcta 18

<210> 34

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: Reverse primer

<400> 34

gcgtcatcat cgtccttgta 20

<210> 35

<211> 16

<212> DNA

<213> Artificial

<220>

<223> Description of artificial sequence: FAM labeled probe

<400> 35

tcttctgcct ggtggt 16